CJC-1295 vs Sermorelin
Two GHRH analogs separated mainly by half-life: Sermorelin is short-acting, CJC-1295 was engineered to last far longer.
In short: Both act on the GHRH receptor; the practical research distinction is duration of action and dosing frequency.
Side-by-side comparison
| CJC-1295 | Sermorelin | |
|---|---|---|
| Class / subtitle | Long-acting GHRH analog | Short-acting GHRH(1-29) analog |
| Research status | In clinical trials | FDA-approved |
| Categories | Growth Hormone | Growth Hormone |
| Primary targets | GHRH receptor | GHRH receptor |
| Half-life | ≈6–8 days with DAC; ≈30 minutes without DAC (Mod GRF 1-29) | ≈10–20 minutes |
| Sequence | Modified GRF(1-29) tetrasubstituted analog with a Drug Affinity Complex (DAC) linker | GRF(1-29)-NH2 (first 29 residues of human GHRH) |
| Molecular formula | C152H252N44O42 | C149H246N44O42S |
| Molecular weight | ≈3647.2 g/mol (with DAC) | 3357.9 g/mol |
| CAS number | 863288-34-0 | 86168-78-7 |
| Routes (research) | subcutaneous | subcutaneous |
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) engineered for a dramatically extended half-life, studied for its ability to raise growth hormone and IGF-1 levels.
Full CJC-1295 profileSermorelin is a GHRH analog made of the first 29 amino acids of growth-hormone-releasing hormone — the shortest fragment that retains full activity. It was FDA-approved for diagnostic and therapeutic use before being commercially discontinued.
Full Sermorelin profileFAQ
What is the main difference between CJC-1295 and Sermorelin?
Both act on the GHRH receptor; the practical research distinction is duration of action and dosing frequency.
What is the half-life of CJC-1295 compared to Sermorelin?
CJC-1295: ≈6–8 days with DAC; ≈30 minutes without DAC (Mod GRF 1-29). Sermorelin: ≈10–20 minutes.
Provided for research and educational reference only — see ourdisclaimer.